- Refractory Hepatic Hydrothorax in Chronic Hepatitis C Controlled by Direct-acting Antivirals
-
Kim MH, Kim DK, Eun HS, Rou WS, Kim SH, Lee BS
- KMID: 2471149
- Korean J Gastroenterol.
- 2020 Feb;75(2):98-102.
- doi: 10.4166/kjg.2020.75.2.98
Hepatic hydrothorax is a transudative pleural effusion that complicates advanced liver cirrhosis. Patients refractory to medical treatment plus salt restriction and diuretics are considered to have refractory hepatic hydrothorax and... -
- CITED
-
- Close
- SHARE
-
- Close
- An integrated analysis of elbasvir/grazoprevir in Korean patients with hepatitis C virus genotype 1b infection
-
Lee YJ, Heo J, Kim DY, Chung WJ, Tak WY, Kim YJ, Paik SW, Sim E, Kulasingam S, Talwani R, Haber B, Hwang P
- KMID: 2467250
- Clin Mol Hepatol.
- 2019 Dec;25(4):400-407.
- doi: 10.3350/cmh.2019.0006
BACKGROUND/AIMS: In the Republic of Korea, an estimated 231,000 individuals have chronic hepatitis C virus (HCV) infection. The aim of the present analysis was to evaluate the safety and efficacy... -
- CITED
-
- Close
- SHARE
-
- Close
- What is the Long-term Benefit of Direct-acting Antiviral Therapy in Chronic Hepatitis C?
-
Kim JW
- KMID: 2460926
- J Korean Med Sci.
- 2019 Oct;34(41):e277.
- doi: 10.3346/jkms.2019.34.e277
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Development and surveillance of hepatocellular carcinoma in patients with sustained virologic response after antiviral therapy for chronic hepatitis C
-
Na SK, Song BC
- KMID: 2459785
- Clin Mol Hepatol.
- 2019 Sep;25(3):234-244.
- doi: 10.3350/cmh.2018.0108
Hepatitis C virus (HCV) infection is a major risk factor for liver cirrhosis and hepatocellular carcinoma (HCC), and is a leading cause of liver-related deaths worldwide. Recently available direct-acting antiviral... -
- CITED
-
- Close
- SHARE
-
- Close
- Comparison of the Clinical Characteristics and Outcomes between Leprosy-Affected Persons in Sorokdo and the General Population Affected by Chronic Hepatitis C in Korea
-
Ahn YH, Park H, Lee MJ, Kim DH, Cho SB, Cho E, Jun CH, Choi SK
- KMID: 2458512
- Gut Liver.
- 2019 Sep;13(5):549-556.
- doi: 10.5009/gnl18432
BACKGROUND/AIMS: Patients with Hansen’s disease are the most vulnerable to hepatitis C. However, no data on the treatment efficacy of direct-acting antiviral agents (DAAs) are available in this group. Therefore,... -
- CITED
-
- Close
- SHARE
-
- Close
- Platelet count is associated with sustained virological response rates in treatments for chronic hepatitis C
-
Jun BG, Park EJ, Lee WC, Jang JY, Jeong SW, Kim YD, Cheon GJ, Cho YS, Lee SH, Kim HS, Lee YN, Kim SG, Kim YS, Kim BS
- KMID: 2457022
- Korean J Intern Med.
- 2019 Sep;34(5):989-997.
- doi: 10.3904/kjim.2017.322
BACKGROUND/AIMS: This study was conducted to clarify the sustained virological response (SVR) prediction ability of baseline and treatment-related factors in patients with chronic hepatitis C virus (HCV) infection. METHODS: This retrospective... -
- CITED
-
- Close
- SHARE
-
- Close
- Prediction and Staging of Hepatic Fibrosis in Children with Hepatitis C Virus: A Machine Learning Approach
-
Barakat NH, Barakat SH, Ahmed N
- KMID: 2457469
- Healthc Inform Res.
- 2019 Jul;25(3):173-181.
- doi: 10.4258/hir.2019.25.3.173
OBJECTIVES: The aim of this study is to develop an intelligent diagnostic system utilizing machine learning for data cleansing, then build an intelligent model and obtain new cutoff values for... -
- CITED
-
- Close
- SHARE
-
- Close
- Daclatasvir and asunaprevir combination therapy for patients with chronic hepatitis C virus genotype 1b infection in real world
-
Oh JY, Kim BS, Lee CH, Song JE, Lee HJ, Park JG, Hwang JS, Chung WJ, Jang BK, Kweon YO, Tak WY, Park SY, Jang SY, Suh JI, Kwak SG
- KMID: 2457309
- Korean J Intern Med.
- 2019 Jul;34(4):794-801.
- doi: 10.3904/kjim.2017.368
BACKGROUND/AIMS: Previous studies have reported a high rate of sustained virologic response (SVR) and a low rate of serious adverse events with the use of daclatasvir (DCV) and asunaprevir (ASV)... -
- CITED
-
- Close
- SHARE
-
- Close
- Evaluation of Noninvasive Liver Fibrosis Blood Markers in Patients with Chronic Hepatitis B and Hepatitis C
-
Lee JH, Cho J, Kim J, Uh Y, Youn KJ
- KMID: 2450840
- Lab Med Online.
- 2019 Jul;9(3):153-160.
- doi: 10.3343/lmo.2019.9.3.153
BACKGROUND: Liver fibrosis evaluation is an important issue in chronic liver disease patients. We aimed to develop noninvasive liver fibrosis biomarkers based on transient elastography (TE, FibroScan®) through retrospective review... -
- CITED
-
- Close
- SHARE
-
- Close
- Direct-acting antivirals response in hepatocellular carcinoma: Does the presence of hepatocellular carcinoma matter?
-
Huang CF, Yu ML
- KMID: 2451919
- Clin Mol Hepatol.
- 2019 Jun;25(2):168-171.
- doi: 10.3350/cmh.2018.1014
During the clinical trial development of directly acting antivirals (DAAs), evidence regarding the treatment efficacy in chronic hepatitis C patients with hepatocellular carcinoma (HCC) was scarce because these patients have... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy of L-carnitine on ribavirin-induced hemolytic anemia in patients with hepatitis C virus infection
-
Sato S, Moriya K, Furukawa M, Saikawa S, Namisaki T, Kitade M, Kawaratani H, Kaji K, Takaya H, Shimozato , Sawada Y, Seki K, Kitagawa K, Akahane T, Mitoro A, Okura Y, Yamao J, Yoshiji H
- KMID: 2447252
- Clin Mol Hepatol.
- 2019 Mar;25(1):65-73.
- doi: 10.3350/cmh.2018.0070
BACKGROUND/AIMS: L-carnitine not only alleviates hyperammonemia and reduces muscle cramps in patients with liver cirrhosis, but also improves anemia in patients with chronic hepatitis and renal dysfunction. This study prospectively... -
- CITED
-
- Close
- SHARE
-
- Close
- Direct-acting antivirals-based therapy decreases hepatic fibrosis serum biomarker microfibrillar-associated protein 4 in hepatitis C patients
-
Mölleken , Ahrens M, Schlosser , Dietz J, Eisenacher M, Meyer HE, Schmiegel , Holmskov U, Sarrazin C, Sorensen G, Sitek B, Bracht T
- KMID: 2447250
- Clin Mol Hepatol.
- 2019 Mar;25(1):42-51.
- doi: 10.3350/cmh.2018.0029
BACKGROUND/AIMS: An estimated 80 million people worldwide are infected with viremic hepatitis C virus (HCV). Even after eradication of HCV with direct acting antivirals (DAAs), hepatic fibrosis remains a risk... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy and Safety of Daclatasvir and Asunaprevir in Patients with Hepatitis C Virus Genotype 1b Infection on Hemodialysis
-
Lee BS, Song MJ, Kwon JH, Lee TH, Jang JW, Kim SH, Lee SH, Kim HS, Kim JH, Kim SB, Ko SY, Song DS
- KMID: 2446804
- Gut Liver.
- 2019 Mar;13(2):191-196.
- doi: 10.5009/gnl18240
BACKGROUND/AIMS: We evaluated the efficacy and safety of daclatasvir (DCV) and asunaprevir (ASV) in patients with chronic hepatitis C virus (HCV) infection on hemodialysis. METHODS: We performed a single-arm, multicenter prospective... -
- CITED
-
- Close
- SHARE
-
- Close
- Management of hepatitis C viral infection in chronic kidney disease patients on hemodialysis in the era of direct-acting antivirals
-
Ko SY, Choe WH
- KMID: 2433297
- Clin Mol Hepatol.
- 2018 Dec;24(4):351-357.
- doi: 10.3350/cmh.2017.0063
The advent of novel, direct-acting antiviral (DAA) regimens for hepatitis C virus (HCV) infection has revolutionized its treatment by producing a sustained virologic response of more than 95% with few... -
- CITED
-
- Close
- SHARE
-
- Close
- Real-World Clinical Efficacy and Tolerability of Direct-Acting Antivirals in Hepatitis C Monoinfection Compared to Hepatitis C/Human Immunodeficiency Virus Coinfection in a Community Care Setting
-
Gayam V, Hossain MR, Khalid M, Chakaraborty S, Mukhtar O, Dahal S, Mandal AK, Gill A, Garlapati , Ramakrishnaiah S, Mowyad K, Sherigar J, Mansour M, Mohanty S
- KMID: 2427460
- Gut Liver.
- 2018 Nov;12(6):694-703.
- doi: 10.5009/gnl18004
BACKGROUND/AIMS: Limited data exist comparing the safety and efficacy of direct-acting antivirals (DAAs) in hepatitis C virus (HCV) monoinfected and HCV/human immunodeficiency virus (HIV) coinfected patients in the real-world clinic... -
- CITED
-
- Close
- SHARE
-
- Close
- The Efficacy and Safety of Direct-acting Antiviral Treatment for Chronic Hepatitis C Patients: A Single Center Study
-
Park SJ, Kim AR, Choe WH, Kim JH, Yoo BC, Kwon SY
- KMID: 2424111
- Korean J Gastroenterol.
- 2018 Oct;72(4):197-204.
- doi: 10.4166/kjg.2018.72.4.197
BACKGROUND/AIMS: Direct-acting antiviral (DAA) therapy has been shown to achieve a high rate of sustained virologic response (SVR) and favorable outcomes in chronic hepatitis C (CHC) patients. We investigated the... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy and safety of sofosbuvir plus ribavirin for Korean patients with hepatitis C virus genotype 2 infection: A retrospective multi-institutional study
-
Kim YM, Kim SB, Song IH, Lee SH, Kim HS, Lee TH, Kang YW, Kim SH, Lee BS, Chae HB, Song MJ, Jang JW, Ko SY, Lee JD
- KMID: 2428759
- Clin Mol Hepatol.
- 2018 Sep;24(3):311-318.
- doi: 10.3350/cmh.2017.0070
BACKGROUND/AIMS: Sofosbuvir plus ribavirin is a standard treatment for patients infected with chronic hepatitis C virus (HCV) genotype 2 in Korea. The purpose of this study was to examine the... -
- CITED
-
- Close
- SHARE
-
- Close
- Does the old-fashioned sofosbuvir plus ribavirin treatment in genotype 2 chronic hepatitis C patients still works for Koreans?
-
Yeon JE
- KMID: 2428755
- Clin Mol Hepatol.
- 2018 Sep;24(3):294-296.
- doi: 10.3350/cmh.2018.1009
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Recent update of the 2017 Korean Association for the Study of the Liver (KASL) treatment guidelines of chronic hepatitis C: Comparison of guidelines from other continents, 2017 AASLD/IDSA and 2016 EASL
-
Yeon JE
- KMID: 2428754
- Clin Mol Hepatol.
- 2018 Sep;24(3):278-293.
- doi: 10.3350/cmh.2018.1002
The paradigm for the treatment of chronic hepatitis C (CHC) has been changed due to the development of direct acting antivirals (DAAs) of hepatitis C virus (HCV). The high sustained... -
- CITED
-
- Close
- SHARE
-
- Close
- 2017 KASL clinical practice guidelines management of hepatitis C: Treatment of chronic hepatitis C
-
The Korean Association for the Study of the Liver (KASL)
- KMID: 2428752
- Clin Mol Hepatol.
- 2018 Sep;24(3):169-229.
- doi: 10.3350/cmh.2018.1004
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
